FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162511661> ?p ?o ?g. }

• W2162511661 endingPage "496" @default.
• W2162511661 startingPage "488" @default.
• W2162511661 abstract "Background. In previous studies of cynomolgus monkey lung allograft recipients, we demonstrated significant immunosuppressive efficacy but reduced tolerability after combined treatment with high doses of microemulsion cyclosporine (CsA) and SDZ RAD (40-O-(2-hydroxyethyl)-rapamycin). The current study was designed to compare efficacy and tolerability of a combination of low-dose CsA and high-dose SDZ RAD (CTL group) to triple therapy using the chimeric anti-interleukin-2 (IL-2) receptor (CD25) monoclonal antibody (mAb) basiliximab (anti-IL-2 receptor mAb) for induction therapy (basiliximab: 5 mg intravenously on days 0 and 4) plus low-dose CsA and low-dose SDZ RAD for maintenance immunosuppression (CD25 group). CsA and anti-IL-2 receptor mAb are drugs that reduce cytokine synthesis and block IL-2-mediated lymphocyte stimulation, respectively. SDZ RAD blocks lymphocyte stimulation by other cytokines (e.g., IL-15) that are not inhibited by anti-IL-2 receptor mAb. Methods. Twelve unilateral lung transplants were performed. Recipients were observed for 49 days by daily weight assessment, hemograms, blood chemistries, radiographs, and lung biopsies. Monkeys were euthanized before day 49 in the event of excessive weight loss (>25%) or organ failure. Target CsA trough levels were 100–200 ng/ml. Target SDZ RAD trough levels in the CTL group (no mAb) were 20–40 ng/ml, and 10–20 ng/ml in the CD25 group. Results. None of the monkeys in the CD25 group needed to be euthanized early due to signs of drug toxicity. In contrast, four monkeys in the CTL group were sacrificed on days 28–35 as a result of excessive weight loss (n=3) and renal functional impairment (n=1). Three recipients in the CD25 group were euthanized on days 36, 38, and 46 as a result of persistent high fever associated with severe rejection. The median animal survival in the CTL group was 32 vs. 46 days in the CD25 group (P <0.04). The only two long-term survivors in the CTL group showed moderate rejection at day 49. The median rejection scores at day 14 (A0) and day 28 (A2) were identical in the two groups, despite the fact that the mean SDZ RAD trough level was significantly lower in the CD25 group (CTL: 38±3 ng/ml, CD25: 18±2 ng/ml, P <0.0001). After basiliximab levels fell below the minimum therapeutic level (1 mg/ml) on day 28, the median rejection score at day 49 increased to A4 in the CD25 group. Conclusion. This is the first study to combine an anti-IL-2 receptor mAb with a drug from the rapamycin class plus CsA. Our study shows that induction therapy with basiliximab enabled SDZ RAD blood levels to be significantly reduced, which led to improved tolerability without the penalty of increased rejection." @default.
• W2162511661 created "2016-06-24" @default.
• W2162511661 creator A5003985388 @default.
• W2162511661 creator A5007589378 @default.
• W2162511661 creator A5025904775 @default.
• W2162511661 creator A5044011869 @default.
• W2162511661 creator A5049232814 @default.
• W2162511661 creator A5052359448 @default.
• W2162511661 creator A5063525307 @default.
• W2162511661 creator A5070662926 @default.
• W2162511661 creator A5072700554 @default.
• W2162511661 creator A5073409460 @default.
• W2162511661 creator A5088941214 @default.
• W2162511661 date "2000-02-01" @default.
• W2162511661 modified "2023-09-26" @default.
• W2162511661 title "PREVENTION OF ACUTE ALLOGRAFT REJECTION IN NONHUMAN PRIMATE LUNG TRANSPLANT RECIPIENTS" @default.
• W2162511661 cites W193383342 @default.
• W2162511661 cites W1979881616 @default.
• W2162511661 cites W1985137297 @default.
• W2162511661 cites W1988271023 @default.
• W2162511661 cites W1996431651 @default.
• W2162511661 cites W2005159788 @default.
• W2162511661 cites W2008800889 @default.
• W2162511661 cites W2019306593 @default.
• W2162511661 cites W2023694008 @default.
• W2162511661 cites W2032607572 @default.
• W2162511661 cites W2066300320 @default.
• W2162511661 cites W2069135659 @default.
• W2162511661 cites W2080595307 @default.
• W2162511661 cites W2134173985 @default.
• W2162511661 cites W2134930343 @default.
• W2162511661 cites W2332754031 @default.
• W2162511661 cites W2441873541 @default.
• W2162511661 cites W68282923 @default.
• W2162511661 doi "https://doi.org/10.1097/00007890-200002270-00005" @default.
• W2162511661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10708100" @default.
• W2162511661 hasPublicationYear "2000" @default.
• W2162511661 type Work @default.
• W2162511661 sameAs 2162511661 @default.
• W2162511661 citedByCount "33" @default.
• W2162511661 countsByYear W21625116612012 @default.
• W2162511661 countsByYear W21625116612013 @default.
• W2162511661 countsByYear W21625116612014 @default.
• W2162511661 countsByYear W21625116612015 @default.
• W2162511661 countsByYear W21625116612016 @default.
• W2162511661 crossrefType "journal-article" @default.
• W2162511661 hasAuthorship W2162511661A5003985388 @default.
• W2162511661 hasAuthorship W2162511661A5007589378 @default.
• W2162511661 hasAuthorship W2162511661A5025904775 @default.
• W2162511661 hasAuthorship W2162511661A5044011869 @default.
• W2162511661 hasAuthorship W2162511661A5049232814 @default.
• W2162511661 hasAuthorship W2162511661A5052359448 @default.
• W2162511661 hasAuthorship W2162511661A5063525307 @default.
• W2162511661 hasAuthorship W2162511661A5070662926 @default.
• W2162511661 hasAuthorship W2162511661A5072700554 @default.
• W2162511661 hasAuthorship W2162511661A5073409460 @default.
• W2162511661 hasAuthorship W2162511661A5088941214 @default.
• W2162511661 hasBestOaLocation W21625116611 @default.
• W2162511661 hasConcept C126322002 @default.
• W2162511661 hasConcept C197934379 @default.
• W2162511661 hasConcept C203014093 @default.
• W2162511661 hasConcept C2776090121 @default.
• W2162511661 hasConcept C2777371288 @default.
• W2162511661 hasConcept C2778375690 @default.
• W2162511661 hasConcept C2778690821 @default.
• W2162511661 hasConcept C2779719350 @default.
• W2162511661 hasConcept C2780252810 @default.
• W2162511661 hasConcept C2781307858 @default.
• W2162511661 hasConcept C2781448352 @default.
• W2162511661 hasConcept C2909675724 @default.
• W2162511661 hasConcept C2911091166 @default.
• W2162511661 hasConcept C71924100 @default.
• W2162511661 hasConcept C79484868 @default.
• W2162511661 hasConcept C8891405 @default.
• W2162511661 hasConcept C98274493 @default.
• W2162511661 hasConceptScore W2162511661C126322002 @default.
• W2162511661 hasConceptScore W2162511661C197934379 @default.
• W2162511661 hasConceptScore W2162511661C203014093 @default.
• W2162511661 hasConceptScore W2162511661C2776090121 @default.
• W2162511661 hasConceptScore W2162511661C2777371288 @default.
• W2162511661 hasConceptScore W2162511661C2778375690 @default.
• W2162511661 hasConceptScore W2162511661C2778690821 @default.
• W2162511661 hasConceptScore W2162511661C2779719350 @default.
• W2162511661 hasConceptScore W2162511661C2780252810 @default.
• W2162511661 hasConceptScore W2162511661C2781307858 @default.
• W2162511661 hasConceptScore W2162511661C2781448352 @default.
• W2162511661 hasConceptScore W2162511661C2909675724 @default.
• W2162511661 hasConceptScore W2162511661C2911091166 @default.
• W2162511661 hasConceptScore W2162511661C71924100 @default.
• W2162511661 hasConceptScore W2162511661C79484868 @default.
• W2162511661 hasConceptScore W2162511661C8891405 @default.
• W2162511661 hasConceptScore W2162511661C98274493 @default.
• W2162511661 hasIssue "4" @default.
• W2162511661 hasLocation W21625116611 @default.
• W2162511661 hasLocation W21625116612 @default.
• W2162511661 hasLocation W21625116613 @default.
• W2162511661 hasOpenAccess W2162511661 @default.
• W2162511661 hasPrimaryLocation W21625116611 @default.

• next